Testosterone Therapy Prevents Gain in Visceral Adipose Tissue and Loss of Skeletal Muscle in Nonobese Aging Men

Allan, Carolyn; Strauss, Boyd Josef Gimnicher; Burger, Henry G.; Forbes, Elise A; McLachlan, Robert I

doi:10.1210/jc.2007-1291

Cited by 259 publications

(198 citation statements)

References 53 publications

Supporting

Mentioning

173

Contrasting

Unclassified

Order By: Relevance

“…As published previously, 20 in response to testosterone, TT levels increased significantly by 30% (by 4-17.7 ± 1.2 nM) in the testosterone group between weeks 0 and 52 (P ¼ 0.014) whereas LH levels fell by 50% in response to testosterone therapy (Po0.001) and were unchanged in the placebo group.…”

Section: Resultssupporting

confidence: 81%

“…20 Data were analysed by a per protocol approach. Changes in sexual function between week 0 and week 26, and week 0 and week 52 were analysed with paired t-tests.…”

Section: Discussionmentioning

confidence: 99%

“…Our testosterone treatment aimed to increase serum TT within the normal range rather than into the supraphysiological range wherein pharmacological effects of testosterone may be seen. We achieved this aim as serum TT increased by 30% into the middle of the healthy young adult male reference range 20 with a reciprocal 50% decline in serum LH serving as a biomarker of increased serum androgenic activity. Men in the testosterone-treated group experienced a significant improvement in sexual desire that was not seen with placebo, however other parameters of sexual function were not influenced by testosterone therapy.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Testosterone therapy increases sexual desire in ageing men with low–normal testosterone levels and symptoms of androgen deficiency

et al. 2008

View full text Add to dashboard Cite

Although decline in sexual function is a common reason for ageing men to seek advice regarding testosterone therapy, placebo-controlled trial data have been unable to show a consistent, beneficial role for testosterone. The objective of this study was to determine the effect of testosterone therapy on sexual function in non-obese ageing men with symptoms of androgen deficiency and low-normal serum testosterone levels. A total of 60 men aged 55 years or older in good general health with total testosterone (TT) levels o15 nM, and with symptoms suggestive of androgen deficiency, were randomized in a double-blinded protocol to transdermal testosterone patches or placebo for 12 months. Sexual function was assessed using the International Index of Erectile Function at weeks 0, 26 and 52. In men receiving testosterone TT levels increased by 30% (P ¼ 0.01) and luteinizing hormone decreased by 50% (Po0.001). Relative to placebo, testosterone therapy improved sexual desire (P ¼ 0.04); however other parameters of sexual function including erectile function were unaffected by the treatment. Ageing men in good general health and with symptoms of androgen deficiency and low-normal serum testosterone levels receiving 12 months of transdermal testosterone therapy experienced, relative to placebo, improved sexual desire but no effect on other parameters of sexual function.

show abstract

Section: Resultssupporting

confidence: 81%

“…20 Data were analysed by a per protocol approach. Changes in sexual function between week 0 and week 26, and week 0 and week 52 were analysed with paired t-tests.…”

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Testosterone therapy increases sexual desire in ageing men with low–normal testosterone levels and symptoms of androgen deficiency

et al. 2008

View full text Add to dashboard Cite

show abstract

“…115,116 However, testosterone therapy increases lean body mass and reduces fat mass, thus modulating insulin resistance and risk of metabolic syndrome. 66,117,118 Testosterone may also exhibit antiatherogenic effects at the tissue level, whether mediated by classical or nonclassical pathways. 119,127,128 The key question is whether testosterone therapy reduces the risk of cardiovascular disease distinct from any effects on erectile dysfunction.…”

Section: Testosterone Cardiovascular Risk and Mortality In Aging Menmentioning

confidence: 99%

Are declining testosterone levels a major risk factor for ill-health in aging men?

Yeap

2008

Int J Impot Res

View full text Add to dashboard Cite

As men grow older, testosterone levels fall, with a steeper decline in unbound or free testosterone compared with total testosterone concentrations. Lower testosterone levels have been associated with poorer cognitive function, and with impaired general and sexual health in aging men. Recently, lower testosterone levels have been linked with metabolic syndrome and type II diabetes, both conditions associated with cardiovascular disease, and shown to predict higher overall and cardiovascular-related mortality in middle-aged and older men. However, reverse causation has to be considered, as systemic illness may result in reduced testosterone levels. Thus, the strength of these associations and the likely direction of causation need to be carefully considered. Furthermore, these conditions may overlap, for example aging, lower testosterone levels, erectile dysfunction and cardiovascular disease are interrelated. Cross-sectional and longitudinal observational studies may be informative. However, ultimately randomized controlled trials of testosterone therapy are needed to clarify its role in the maintenance of general and sexual health in aging men. Testosterone therapy should be considered in hypogonadal men who meet rigorous criteria for the diagnosis of androgen deficiency. Additional consideration should be given to designing and testing interventions that may prevent or ameliorate the age-related decline in testosterone levels in men.

show abstract

“…In the past decade evidence has been produced of the benefit of androgen treatment on multiple target organs of hypogonadal men, and recent studies show short-term beneficial effects of testosterone in older men that are similar to those in younger men [34][35][36][37].…”

Section: Benefits Of Testosterone Of Replacement Therapymentioning

confidence: 99%

Androgens and male aging: current evidence of safety and efficacy

Gooren¹

2010

Asian J Androl

View full text Add to dashboard Cite

Many signs of aging, such as sexual dysfunction, visceral obesity, impaired bone and muscle strength, bear a close resemblance to features of hypogonadism in younger men. The statistical decline of serum testosterone in aging men is solidly documented. It has been presumed that the above features of aging are related to the concurrent decline of androgens, and that correction of the lower-than-normal circulating levels of testosterone will lead to improvement of symptoms of aging. But in essence, the pivotal question whether the age-related decline of testosterone must be viewed as hypogonadism, in the best case reversed by testosterone treatment, has not been definitively resolved. Studies in elderly men with lower-than-normal testosterone report improvement of features of the metabolic syndrome, bone mineral density, of mood and of sexual functioning. But as yet there is no definitive proof of the beneficial effects of restoring testosterone levels to normal in elderly men on clinical parameters. Few of these studies meet as yet rigorous standards of scientific enquiry: double-blind, placebo-controlled design of the study. The above applies also to the assessment of safety of testosterone administration to elderly men. There is so far no convincing evidence that testosterone is a main factor in the development of prostate cancer in elderly men and guidelines for monitoring the development of prostate disease have been developed. It is of note that there are presently no long-term safety data with regard to the prostate. Polycythemia is another potential complication of testosterone treatment. It is dose dependent and can be managed with dose adjustment.

show abstract

Testosterone Therapy Prevents Gain in Visceral Adipose Tissue and Loss of Skeletal Muscle in Nonobese Aging Men

Cited by 259 publications

References 53 publications

Testosterone therapy increases sexual desire in ageing men with low–normal testosterone levels and symptoms of androgen deficiency

Testosterone therapy increases sexual desire in ageing men with low–normal testosterone levels and symptoms of androgen deficiency

Are declining testosterone levels a major risk factor for ill-health in aging men?

Androgens and male aging: current evidence of safety and efficacy

Contact Info

Product

Resources

About